Maui Derm

Ilona Frieden, MD, highlights her session at Maui Derm Hawaii on new therapies for treating pediatric cases in dermatology.

Maui Derm is underway in Maui, Hawaii, offering a multitude of presentations and workshops for the dermatology community.

Experts at Maui Derm Hawaii offer the latest findings and research in treating acne vulgaris in adolescents.

Enjoy fun in the sun when Maui Derm Hawaii 2023 presentations aren’t in session.

Maui Derm founder, George Martin, MD, gives a preview of the 2023 Maui Derm Hawaii Dermatology Conference at the Grand Wailea Resort on Maui.

Suzanne Kilmer, MD, Founder of the Laser & Skin Surgery Center of Northern California, and clinical professor at the University of California talks about why she is excited for Maui Derm Hawaii 2023.

Neal Bhatia, MD, gives insight into his shared sessions at the 2023 Maui Derm Hawaii conference.

Aloha! The 2023 Maui Derm Hawaii Dermatology Conference begins today at the Grand Wailea Resort on Maui.

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

In a grand rounds presentation at the Maui Derm NP+PA Fall 2021 conference, Seemal Desai, MD, FAAD, Raegan Hunt, MD, PhD, Ted Rosen, MD, and Matthew J. Zirwas, MD, discussed some of their challenging cases.

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

In his presentation at Maui Derm NP+PA Fall 2021, Jerry Shapiro, MD, FAAD, shared his treatment protocols for lupus erythematosus, lichen planopilaris, folliculitis decalvans, and dissecting cellulitis.

Learning to identify some well-disguised drivers of eczema and contact dermatitis can speed patients toward clear or almost clear, according to a presentation at Maui Derm NP+PA Fall 2021.

Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

At Maui Derm NP+PA Fall 2021, George Martin, MD, discussed his opinion on best treatment options for SCC in situ and cutaneous SCC at high risk for metastasis along with BCC that require special considerations.

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.

A review of the American Academy of Dermatology guidelines and current treatment improvements for actinic keratosis were discussed during a presentation at Maui Derm NP+PA Fall 2021.

Potential game-changers in the pipeline and newly FDA-approved treatments were highlighted in an overview of new drugs to watch at Maui Derm NP+PA Fall 2021 meeting.

As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.

Expert panelists outline best practices to set up nurse practitioners (NPs) and physician assistants (PAs) for success in injecting neuromodulators and dermal fillers as part of the preconference track at Maui Derm NP+PA Fall 2021 .

The Maui Derm NP+PA Fall 2021 8th Annual Meeting begins today with an in-person, 4-track preconference program at the Omni Grove Park Inn in Asheville, North Carolina. Continue to check in for the next 3 days for the latest coverage of the main program which is from September 30 to October 3.

Regenerative medicine is still in its infancy, but patient demand and ease of use are growing its popularity among dermatologists. However, regulatory issues raise concerns.

Data from trials show tazarotene 0.045% lotion is an effective treatment for moderate to severe facial acne and improves acne-related QOL in patients across BMI categories.

A presentation from Maui Derm Live 2021 featured insights on new drugs and data in acne.

Expert offers tips on understanding and complying with regulations governing this growing sector.

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

This formulation could be first FDA-approved single-agent E-BPO prescription drug to treat rosacea.